JCR Pharmaceuticals Co Ltd (4552)

Tokyo
Currency in JPY
556.0
+13.0(+2.39%)
Delayed Data
4552 Scorecard
Full Analysis
RSI suggests the stock is in oversold territory
Earnings results expected in 7 days
Fair Value
Day's Range
544.0558.0
52 wk Range
466.01,120.0
Key Statistics
Edit
Bid/Ask
555.00 / 556.00
Prev. Close
543
Open
545
Day's Range
544-558
52 wk Range
466-1,120
Volume
151.8K
Average Volume (3m)
381.46K
1-Year Change
-52.09%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
4552 Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
880.0
Upside
+58.27%
Members' Sentiments
Bearish
Bullish
ProTips
Prominent player in the Pharmaceuticals industry
Show more

JCR Pharmaceuticals Co Ltd Company Profile

JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells, imports, and exports medical devices and laboratory instruments; and purchases and sells medical and research equipment. The company has a collaboration agreement with Angelini Pharma for the development of novel biologic therapies; and a. joint research agreement with Modalis Therapeutics Corporation to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.

Employees
934
Market
Japan

Compare 4552 to Peers and Sector

Metrics to compare
4552
Peers
Sector
Relationship
P/E Ratio
−151.4x13.0x−0.6x
PEG Ratio
1.440.020.00
Price/Book
1.2x0.9x2.6x
Price / LTM Sales
1.9x1.4x3.1x
Upside (Analyst Target)
23.2%11.4%53.1%
Fair Value Upside
Unlock15.0%7.5%Unlock

Analyst Ratings

2 Buy
5 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 880.0
(+58.27% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS -3.5
Dividend Yield
3.65%
Industry Median 2.28%
Annualised payout
20
Paid unevenly
5-Years Growth
+36.31%
Growth Streak

Earnings

Latest Release
Oct 30, 2024
EPS / Forecast
-7.14 / 13.72
Revenue / Forecast
8.51B / 11.26B
EPS Revisions
Last 90 days

FAQ

What Is the JCR Pharmaceuticals (4552) Stock Price Today?

The JCR Pharmaceuticals stock price today is 556.00

What Stock Exchange Does JCR Pharmaceuticals Trade On?

JCR Pharmaceuticals is listed and trades on the Tokyo stock exchange.

What Is the Stock Symbol for JCR Pharmaceuticals?

The stock symbol for JCR Pharmaceuticals is "4552."

Does JCR Pharmaceuticals Pay Dividends? What’s The Current Dividend Yield?

The JCR Pharmaceuticals dividend yield is 3.68%.

What Is the JCR Pharmaceuticals Market Cap?

As of today, JCR Pharmaceuticals market cap is 67.86B.

What is JCR Pharmaceuticals Earnings Per Share?

The JCR Pharmaceuticals EPS is -3.50.

What Is the Next JCR Pharmaceuticals Earnings Date?

JCR Pharmaceuticals will release its next earnings report on 30 Jan 2025.

From a Technical Analysis Perspective, Is 4552 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.